Across TCGA pan-cancer cohorts, LMBR1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LMBR1L data layer compared with 25 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher LMBR1L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LMBR1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
READ, LIHC, and UCEC are the cancer types where LMBR1L Mutation most reproducibly stratifies survival.